AmVac AG Granted Patent for new Vaccine Development

ZUG, Switzerland, April 1, 2010 - The Swiss company AmVac AG, a biopharmaceutical company
located in Zug, has been granted a European patent (EP 1851 239 B1) for its
Sendai platform technology for its subsidiary company AmVac Research GmbH.
Thus, the novel technology for producing vaccines that has been developed at
the research site in Martinsried near Munich, Germany, is completely covered
by the granted patent. The patent was granted effective of January 21, 2009
in 29 EPC (European Patent Convention) countries. A communication was issued
by the European Patent Office that no opposition has been filed against said
patent within the statutory nine months term for doing so.

The patent for the Sendai platform technology broadly covers
its use for any recombinant, replication deficient negative-strand RNA virus
with a mutation in the so-called P-gene. This broad protection covers all
development activities in relation to the Sendai platform technology for
developing vaccines against a number of infectious diseases.

This technology, which has been developed by Prof. Wolfgang
Neubert's group at the Max Planck Institute of Biochemistry, is to be used
for numerous indications in the future. AmVac Research GmbH is concentrating
on providing protection against respiratory syncytial virus (RSV) in the
development of its first vaccine. This viral pathogen causes serious airway
diseases which can lead to loss of function of the mucous membranes in the
respiratory tract. Young children, the elderly, and individuals with a
weakened immune system are particularly affected by this flu-like viral
disease.

AmVac AG has filed the entire patent family beyond the borders of the EU
in the other countries Australia, Brazil, Canada, China, Hong-Kong, Eurasia,
Israel, India, Japan, Korea, Mexico, Singapore, The United States, and South
Africa. AmVac AG has already been successful in Mexico and South Africa. Both
countries have granted patents with the same scope of protection as in
Europe.

AmVac AG

AmVac AG is a biopharmaceutical company situated in
Switzerland. The company focuses on the vaccine market with its above-average
growth figures. There are two therapeutic vaccines in the pipeline, which are
soon to be launched in the fields of gynaecology and urology. Further
innovative vaccines and technologies are at the development stage. The
renowned market research company Frost & Sullivan awarded AmVac AG the
coveted prize "Enabling Technology of the Year Award" in 2007.

Contact:

Ariane Meynert, Head of PR/IR; Mail: meynert@amvac.ch Tel.:
+41-41-725-3234, Cell: +41-79-79-334-19

Contact: Ariane Meynert, Head of PR/IR; Mail: meynert at amvac.ch Tel.: +41-41-725-3234 Cell: +41-79-79-334-19